Sign in
CompletedPhase 4

Pregabalin Versus Dexmedetomidine for Delirium Prevention After Cardiac Surgery

Key facts

Who runs it
Tanta University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
60 people enrolled
Started
15 Dec 2022
Ended
2 Jan 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Pregabalin
  • Dexmedetomidine
Record updated
7 January 2025

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • ≥ 65 years of age both genders American Society of Anesthesiologists (ASA) physical status classification II or III scheduled for cardiac surgery

Who cannot take part

  • Patients who had history of psychiatric diseases; inability to communicate; previous history of POD; preoperative sick sinus syndrome
  • Previous cardiac or thoracic surgery
  • Allergy/sensitivity to pregabalin or dexmedetomidine
  • Severe bradycardia (heart rate <50 beat per minute)
  • Severe hepatic or renal insufficiency
  • Known diagnosis of depression or other major psychiatric diseases
  • Cognitive impairment or inability to cooperate with the study
  • Renal insufficiency, and history of substance abuse
  • Second-degree or above atrioventricular block without pacemaker

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study is to compare the effect of perioperative administration of pregabalin versus dexmedetomidine on the prevalence and lasting duration of delirium in elderly patients after cardiac surgery.

The 2 groups in the trial

  • pregabalin groupExisting treatment, for comparison

    patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 h for 24h postoperatively by nasogastric tube or orally. Patients will receive IV saline as placebo with the same rate of dexmedetomidine.

    Treatment: Pregabalin

  • dexmedetomidine groupExisting treatment, for comparison

    patients in the dexmedetomidine group will receive after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h. Patients will receive placebo 2 h prior to induction of anesthesia and every 12 h for 24h postoperatively by nasogastric tube or orally. If patients are hemodynamically unstable, the bolus dose will be omitted. The infusion of dexmedetomidine will be continued for a maximum period of 24 h. Dexmedetomidine infusion will be not discontinued before extubation.

    Treatment: Dexmedetomidine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pregabalin Versus Dexmedetomidine for Delirium Prevention After Cardiac Surgery: A Randomized Double-Blind Trial
Record updated
7 January 2025